Triglyceride-Lowering Therapies: Addressing Gaps in the Guidelines

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Robert Kloner, Vice President of Translation at Huntington Medical Research Institutes and Professor of Medicine in the Cardiovascular Division of Keck School of Medicine at the University of Southern California. Dr. Kloner discusses the cardiovascular risk factors associated with erectile dysfunction, safety and efficacy of erectile disfunction drugs, and benefits vs risks of supplementing with testosterone.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Rhoda Cooper-DeHoff. Dr. Cooper-DeHoff is an Associate Professor in the Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine of the Colleges of Pharmacy and Medicine at the University of Florida. She is also Associate Director of the Center for Pharmacogenomics at this institution. Dr. Cooper-DeHoff discusses the rise of pharmacometabolomics, genomic testing, and pharmacogenetic testing in lipidology, with particular emphasis on predictive mapping for statin responses.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dave Dixon, PharmD, Clinical Pharmacist and Associate Professor of Pharmacology at Virginia Commonwealth University School of Pharmacy. Dr. Dixon is also a Board Certified Pharmacotherapy Specialist, Clinical Lipid Specialist, and Fellow of the National Lipid Association. He serves as a Regional Representative for the Southeast Chapter of NLA and on the Journal of Clinical Lipidology Editorial Board. Dr. Dixon discusses guidelines for treating hypertriglyceridemia, effective therapies for reducing triglyceride levels, and emerging lipid-lowering therapies in development.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Eugenia Gianos. Dr. Gianos is an assistant professor in the Department of Medicine and co-clinical director of the Center for the Prevention of Cardiovascular Disease at the NYU School of Medicine. Dr. Gianos discusses the effectiveness, potential side effects, and patient outcomes with PCSK9 antibodies for management of dyslipidemia.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Like in the United States, Canadian citizens contend with a high pediatric prevelance of lipid disorders, particularly familial hypercholesterolemia. However, perspectives on clinical care and standards public health priorities to address dyslipidemia differ markedly between these two countries. Can American practitioners and health policy experts alike benefit from Canadian approaches to lipidology? Dr. Alan Brown welcomes Dr. Julie St. Pierre, Professor of Pediatrics at Sherbrooke University in Canada, to discuss pediatric lipid disorder management across North American borders.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Patients in lipidolgy clinics sometimes undergo diagnostic workups for mild liver enzyme elevations, and in select cases a diagnosis of non-alcoholic fatty liver disease will be made. How does this diagnosis compare with the more inflammatory alcoholic fatty liver disease, and what roles should the lipidologist play in response to these findings? Dr. David Cohen, Professor of Medicine at Harvard Medical School and Director of Hepatology at Brigham and Women's Hospital, joins host Dr. Alan Brown to discuss the pathogenesis and management of non-alcoholic fatty liver disease.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Joining Dr. Alan Brown to discuss the pharmacokinetic data behind drug interactions between treatments for complex lipid abnormalities is Dr. Barbara Wiggins, Pharm.D, clinical pharmacy specialist in cardiology at the Medical University of South Carolina and adjunct professor at the South Carolina School of Pharmacy. Dr. Wiggens has served as a member of the cardiovascular expert panel for the United States Pharmacopoeia.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Robert Wild, MD, MPH, D.Phil. Recorded live at the recent Annual National Lipid Association meeting, Dr. Alan Brown welcomes Dr. Robert Wild to discuss types of dyslipidemia that clinicans may see in women of child bearing age, particularly those using hormonal contraception. The two discuss ways for clinicians to trace the source of dyslipidemia in these women, from primary to secondary causes, and how this knowledge can guide future contraception choices. Dr. Robert Wild is Professor of OB/GYN and Adjunct Professor in Biostatistics and Epidemiology at the University of Oklahoma. He is also Adjunct Professor in Epidemiology at the University of Pittsburgh, and Adjunct Professor of Nutrition at Oklahoma State University.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Joyce Ross Host Dr. Alan Brown welcomes Joyce Ross, nurse practitioner and President of the National Lipid Association. Joyce is a consultative education specialist in Cardiovascular Risk Intervention with the University of Pennsylvania Health System. She is the first Nurse Practitioner elected as President of the NLA. Ms. Ross introduces her goals for the upcoming year, including novel efforts on behalf of the NLA to help combat America's obesity epidemic.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Host Dr. Alan Brown welcomes Dr. Seth Martin, cardiologist and assistant professor of medicine at the Johns Hopkins University School of Medicine with a joint appointment in epidemiology at the Johns Hopkins Bloomberg School of Public Health. Dr. Martin is a faculty member in the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease. Dr. Martin discusses the pursuit of lipid profiles on a national level, utilizing Big Data from health records and clinical trials to develop better understandings of cardiovascular risk and theraputic efficacies.